We keep challenging
About SolasiaCommercial products
ProductsPharmaceuticals – thinking each of you
PipelineFor living brilliant future together
IR InformationDevelopment Strategy
- Solasia
- Other Companies
Pharmaceuticals
-
- Pipeline Code
- Estimated Initial indication
- Originator
- Pre-
clinical - Clinical Study
Phase 1 - Clinical Study
Phase 2 - Clinical Study
Phase 3 - NDA
- Approval
- Launch
- Partner
-
SP-01
Chemotherapy Induced Nausea and Vomiting
ProStrakan(Kyowa Kirin)overview -
China (Solasia)Taiwan, Singapore etc. (Kyowa Hakko Kirin : Sublicensee)US, EU, over 10 countries(Sancuso®by other companies)
-
- Kyowa Hakko Kirin:
- Hong Kong, Macau, Taiwan, Malaysia, Singapore
- Lee’s Pharma:
- China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau
-
SP-02
Peripheral T-Cell Lymphoma
ZIOPHARM Oncology, Incoverview -
Japan, Korea, Taiwan, HK (Phase II, pivotal Study)China (Phase II/III, pivotal study preparation)US (Phase IIA, completion)EU (Pre-clinical, completion)
-
- Meiji Seika Pharma:
- Japan
- HB Human BioScience SAS:
- Latin America
-
SP-04
Chemotherapy Induced Peripheral Neuropathy (CIPN)
PledPharma ABoverview -
Japan, South Korea, Taiwan, HK (Phase III)ChinaUS and EU (Phase III by PledPharma)
Medical Device
-
- Pipeline Code
- Estimated Initial indication
- Originator
- Pre-clinical
- Clinical Study
- NMDA
- Approval
- Launch
- Partner
-
SP-03
Pain associated oral mucositis
Camurus ABoverview -
JapanChinaKoreaUS, EU, over 9 countries (episil® by other companies)
-
- Meiji Seika Pharma:
- Japan
- Lee’s Pharma:
- China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan
Pharmaceuticals
- Pipeline Code
- SP-01
- Estimated Initial indication
- Chemotherapy Induced Nausea and Vomiting
- Originator
- ProStrakan(Kyowa Kirin)
- Pre-
clinical - Clinical
Study
Phase 1 - Clinical
Study
Phase 2 - Clinical
Study
Phase 3 - NDA
- App-
roval - Lau-
nch
China (Solasia)
Taiwan, Singapore etc. (Kyowa Hakko Kirin : Sublicensee)
US, EU, over 10 countries(Sancuso®by other companies)
- Partner
-
- Kyowa Hakko Kirin
- Hong Kong, Macau, Taiwan, Malaysia, Singapore
-
- Lee’s Pharma
- China Mainland w/o Beijing, Shanghai, Guangzhou, Hong Kong and Macau
- Pipeline Code
- SP-02
- Estimated Initial indication
- Peripheral T-Cell Lymphoma
- Originator
- ZIOPHARM Oncology, Inc
- Pre-
clinical - Clinical
Study
Phase 1 - Clinical
Study
Phase 2 - Clinical
Study
Phase 3 - NDA
- App-
roval - Lau-
nch
Japan, Korea, Taiwan, HK (Phase II, pivotal Study)
China (Phase II/III, pivotal study preparation)
US (Phase IIA, completion)
EU (Pre-clinical, completion)
- Partner
-
- Meiji Seika Pharma
- Japan
-
- HB Human BioScience SAS
- Latin America
- Pipeline Code
- SP-04
- Estimated Initial indication
- Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Originator
- PledPharma AB
- Pre-
clinical - Clinical
Study
Phase 1 - Clinical
Study
Phase 2 - Clinical
Study
Phase 3 - NDA
- App-
roval - Lau-
nch
Japan, South Korea, Taiwan, HK (Phase III)
China
US and EU (Phase III by PledPharma)
- Partner
Medical Device
- Pipeline Code
- SP-03
- Estimated Initial indication
- Pain associated oral mucositis
- Originator
- Camurus AB
- Pre-
clinical - Clinical Study
- NMDA
- Approval
- Launch
Japan
China
Korea
US, EU, over 9 countries (episil® by other companies)
- Partner
-
- Meiji Seika Pharma
- Japan
-
- Lee’s Pharma
- China Mainland w/o Beijing, Shanghai, Guangzhou and Taiwan